Effect of broccoli seed and sprout extract on tobacco carcinogens in heavy smokers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II trial investigates whether broccoli seed and sprout extract can help break down cancer-causing substances from tobacco in heavy smokers. The study aims to measure the urinary excretion of specific tobacco carcinogens after a 12-week supplementation period. Participants will be randomized to receive either the extract or a placebo, and their safety and tolerability will be monitored. Additionally, the study will explore genetic factors that may influence detoxification processes related to tobacco exposure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female current tobacco smokers with \>= 20 pack years of self-reported smoking exposure and a current average use of \>= 10 cigarettes/day
* Age \>= 18 years. No upper age limit
* Karnofsky performance scale \>= 70%
* Absolute neutrophil count \>= 1,000/microliter
* Platelets \>= 100,000/microliter
* Total bilirubin =\< 2 x institutional upper limit of normal (ULN)
* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 x ULN
* Creatinine =\< 1.5 x ULN
* Participants with known human immunodeficiency virus (HIV) infection are not eligible for this trial due to potential interaction between sulforaphane and anti-retroviral therapy
* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with HCV infection who are currently on treatment are not eligible due to potential interaction between sulforaphane and anti-retroviral therapy
* The effects of BSSE on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* History of invasive cancer within the past 2 years, except for excised and cured non-melanoma skin cancer or carcinoma in situ of the cervix. Participants who continue adjuvant treatment for an index cancer occurring \> 2 years ago, such as adjuvant hormonal therapy for breast cancer, are excluded. Participants who are on anti-neoplastic treatment for a chronic malignancy, such as multiple myeloma or chronic myelogenous leukemia, are excluded
* Ongoing use of a nutraceutical or dietary supplement containing glucoraphanin or sulforaphane

  * Note, participants will be eligible if they agree to stop the glucoraphanin or sulforaphane product at least 7 days prior to the baseline visit (7-day washout)
* Participants with known chronic hepatitis B virus (HBV) infection are not eligible for this trial due to potential interaction between sulforaphane and suppressive anti-viral therapy
* Participants may not be receiving any other investigational agents
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Avmacol ES® (BSSE)
* Uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
* Any other condition or lifestyle factor, that, in the opinion of the principal investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
* Pregnant or lactating women. Pregnant women are excluded from this study because the effects of BSSE on the developing human fetus are unknown. Because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with BSSE, Breastfeeding should be discontinued if the mother is treated with BSSE

Where it's running

• University of Arizona Cancer Center - Prevention Research Clinic
  Tucson, Arizona, United States Recruiting
• George Washington University Medical Center
  Washington D.C., District of Columbia, United States Recruiting
• Roswell Park Cancer Institute
  Buffalo, New York, United States Recruiting

Study contacts

• Principal investigator: Julie E Bauman — George Washington University Cancer Center

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nicotine's Effects on Eye Movements in E-Cigarette Users

  This study tests how nicotine from e-cigarettes affects eye movements and related behaviors in adults who regularly use nicotine-containing e-cigarettes.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07604246

• Tobacco and cannabis co-use: how young adults start, escalate, and maintain dual use

  This project sees how 18–30-year-olds who use cannabis weekly start, escalate, and keep using either daily cigarettes or daily nicotine vapes.

  Recruiting Roswell Park Cancer Institute · Buffalo, New York · NCT07439471

• Carcinogen and toxicant exposure among young adults who co-use e-cigarettes and cannabis

  This project will measure nicotine, cannabis, and toxicant levels in blood and urine and compare use behaviors in 18–25-year-olds who primarily use e-cigarettes, cannabis, or both.

  Recruiting Roswell Park Cancer Institute · Buffalo, New York · NCT07167225

• How menthol and cooling agents change the appeal of oral nicotine pouches

  This test checks whether menthol, a synthetic cooling agent (WS-3), or both make oral nicotine pouches more appealing and better at relieving cravings for adult cigarette smokers.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07111234

• Testing how well smokers can identify cigarette flavors

  This study tests how well daily smokers can recognize different flavors in menthol cigarettes to understand how it affects their smoking habits.

  Recruiting Early Phase 1 Roswell Park Cancer Institute · Buffalo, New York · NCT06816459

• Oral nicotine pouches versus patches and lozenges to reduce cigarette use in rural Appalachia

  This compares oral nicotine pouches with nicotine patches and lozenges to see if they help adults in rural Appalachia who smoke cut down or quit cigarettes.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06763536

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.